Do U have problems
いいねしてコメントしました
$テスラ (TSLA.US)$だから、正直な質問です:マーケットによって誰もが永遠にテスラの車を買うことを余儀なくされると決まったのでしょうか? 私たちは単に、テスラが全米GDPを超えることを期待すべきでしょうか?
友達のために尋ねます。
友達のために尋ねます。
翻訳済み
17
8
Do U have problems
がいいねしました
Vaccine makers have thus far been hesitant to tweak existing coronavirus jabs due to fears it could become a game of whack-a-mole, but a super strain may change that sentiment. Testing involving Omicron is already underway among the big manufacturers, with several saying it would take about two weeks to establish whether the new variant renders their shots less effective. On Friday, South Africa's health minister said he expects current jabs to still offer protection against severe illness and death from Omicron, though they might be less effective at preventing infections and milder disease.
In case it doesn't: $ファイザー (PFE.US)$ and partner $バイオエヌテック (BNTX.US)$ said they would be able to adapt their vaccines within six weeks, and ship initial batches within 100 days in the event of an escape variant. Moderna can meanwhile get a new construct into human trials in less than 60 days, though manufacturing would take a few months. Any new candidates would also need to clear the regulatory process, getting a green light from the Food and Drug Administration.
In terms of therapeutics, Pfizer's Paxlovid and $メルク (MRK.US)$ molnupiravir are expected to target parts of the virus that are not changed in Omicron, and could be all the more important if vaccine-induced and natural immunity are threatened. Both drugmakers have licensed their antiviral pills to other manufacturers, so they should be widely available if needed. The Biden administration has even ordered 13M courses of the two drugs after seeing significant success in trials at preventing severe illness in high-risk groups.
Outlook: Regarding manufactured antibodies, Omicron's mutations are likely to render some treatments ineffective, according to Dr. David Ho, professor of microbiology and immunology at Columbia University. Investors are particularly worried about antibody drugs from $リジェネロン ファーマシューティカルズ (REGN.US)$ and $イーライ リリィ (LLY.US)$, but some think $ヴィル バイオテクノロジー (VIR.US)$ and $アストラゼネカ (AZN.US)$ could hold up better against this variant due to the way the antibodies are constructed to target the spike proteins. The new variant might also dull the impact of monoclonal antibody treatment because of those same mutations, said Dr. Wendy Barclay, head of the G2P-UK National Virology Consortium.
In case it doesn't: $ファイザー (PFE.US)$ and partner $バイオエヌテック (BNTX.US)$ said they would be able to adapt their vaccines within six weeks, and ship initial batches within 100 days in the event of an escape variant. Moderna can meanwhile get a new construct into human trials in less than 60 days, though manufacturing would take a few months. Any new candidates would also need to clear the regulatory process, getting a green light from the Food and Drug Administration.
In terms of therapeutics, Pfizer's Paxlovid and $メルク (MRK.US)$ molnupiravir are expected to target parts of the virus that are not changed in Omicron, and could be all the more important if vaccine-induced and natural immunity are threatened. Both drugmakers have licensed their antiviral pills to other manufacturers, so they should be widely available if needed. The Biden administration has even ordered 13M courses of the two drugs after seeing significant success in trials at preventing severe illness in high-risk groups.
Outlook: Regarding manufactured antibodies, Omicron's mutations are likely to render some treatments ineffective, according to Dr. David Ho, professor of microbiology and immunology at Columbia University. Investors are particularly worried about antibody drugs from $リジェネロン ファーマシューティカルズ (REGN.US)$ and $イーライ リリィ (LLY.US)$, but some think $ヴィル バイオテクノロジー (VIR.US)$ and $アストラゼネカ (AZN.US)$ could hold up better against this variant due to the way the antibodies are constructed to target the spike proteins. The new variant might also dull the impact of monoclonal antibody treatment because of those same mutations, said Dr. Wendy Barclay, head of the G2P-UK National Virology Consortium.
![TRIGGER WARNING: What will Omicron mean for antibody treatments?](https://ussnsimg.moomoo.com/7795882953875396090.jpg/thumb)
23
8
Do U have problems DianaSun_02 : 皮肉に気づかない人のために、米国政府はテスラを無視するために全力を尽くしています。代わりに、レガシー自動車メーカーを称賛、助成、宣伝するために全力を尽くしています。しかし、テスラは米国で電気自動車を製造している唯一の会社です。Lucidはまだ始まったばかりです。それは最高に陳情的な資本主義の臭いがします。